Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Danicopan Modified Release Formulations in Healthy Subjects
NCT03384186Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoints: Time To Maximum Observed Concentration, Maximum Observed Concentration and 1 more. Started Dec 2017; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03384186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384186.